Author

N. M. Arora

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:protein structure· 1

Frequent Co-Authors

P. K. Kundu· 4 shared R. gupta· 3 shared S. Mazumder· 3 shared A. Baru· 2 shared A. Naqvi· 2 shared A. Srivastava· 2 shared B. Kumar· 2 shared B. P. Das Purkayastha· 2 shared

Activity by Year

2020-2020 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

P. K. Kundu

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cancer BiologybioRxivPreprintDec 21, 2020

Recapitulating tumor microenvironment using preclinical 3D tissueoids model for accelerating cancer research and drug screening

A. Baru, S. Mazumder, P. K. Kundu…·N. M. Arora

This study develops a 3D tissueoids model using the AXTEX-4D platform to better simulate tumor microenvironment and drug resistance compared to 2D and collagen-based 3D systems.

DOI 10.1101/2020.12.21.423825

experimental assaycancer & tumor microenvironment

𝕏 PostBluesky

ImmunologybioRxivNov 5, 2020

AXTEX-4D™: A Novel 3D ex vivo platform for preclinical investigations of immunotherapy agents

A. Baru, S. Sharma, B. P. Das Purkayastha…·N. M. Arora

The paper introduces AXTEX-4D, a 3D ex vivo platform for testing immunotherapy drugs by mimicking the tumor microenvironment to assess immune cell responses and drug efficacy.

DOI 10.1089/adt.2021.031

experimental assaydrug response / drug discovery

𝕏 PostBluesky

ImmunologybioRxivOct 30, 2020

PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2

S. Mazumder, R. Rastogi, A. Undale…·P. K. Kundu

This paper develops a triple antigen VLP vaccine candidate, PRAK-03202, against SARS-CoV-2 and shows it induces neutralizing antibodies and Th1 immune responses in mice.

DOI 10.1016/j.heliyon.2021.e08124

mouseproteomics

𝕏 PostBluesky

BiochemistrybioRxivPreprintMay 18, 2020

Multi-Antigenic Virus-like Particle of SARS CoV-2 produced in Saccharomyces cerevisiae as a vaccine candidate

K. Arora, R. Rastogi, N. M. Arora…·P. K. Kundu

The paper reports the production of a multi-antigenic SARS CoV-2 virus-like particle (VLP) in Saccharomyces cerevisiae as a vaccine candidate, confirmed by TEM and analytical data.

DOI 10.1101/2020.05.18.099234

yeastprotein structure

𝕏 PostBluesky